Literature DB >> 18671471

Eprodisate in amyloid A amyloidosis: a novel therapeutic approach?

Lucio Manenti1, Pius Tansinda, Augusto Vaglio.   

Abstract

BACKGROUND: Amyloid A (AA) amyloidosis can complicate chronic inflammatory diseases, chronic infections and recurrent periodic fever syndromes. Its treatment is challenging, given its heterogeneous spectrum of etiologies.
OBJECTIVE: To review the available literature regarding treatment options for AA amyloidosis, particularly focusing on eprodisate, a newly developed inhibitor of fibrillogenesis.
METHODS: A PubMed search was performed without any date limits, mainly using the search terms 'amyloidosis', 'colchicine', 'eprodisate', '1,3-propanedisulfonate', 'NC-503', 'Fibrillex' and 'TNF-blockers'. RESULTS/
CONCLUSION: Antibiotics and colchicine are effective in preventing and treating infection-related and familial Mediterranean fever-related AA amyloidosis, respectively. Recently, TNF-alpha blockers have emerged as effective agents in inflammatory AA amyloidosis. Eprodisate binds to the glycosaminoglycan binding site on amyloid fibrils, thus targeting amyloid fibril polymerization and tissue deposition. Eprodisate has possible applicability to other types of amyloidosis; the results of a recent randomized trial showed that it may slow the progression of AA amyloidosis-related renal disease but confirmatory studies are necessary.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18671471     DOI: 10.1517/14656566.9.12.2175

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  4 in total

1.  AA amyloidosis associated with macroglobulinemia.

Authors:  Raine Tatara; Tadashi Nagai; Hiroyuki Kobayashi; Kaoru Hatano; Takahiro Suzuki; Kazuo Muroi; Keiya Ozawa
Journal:  Int J Hematol       Date:  2010-10-16       Impact factor: 2.490

2.  [Amyloidoses].

Authors:  S Ladner-Merz; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2008-12       Impact factor: 1.372

Review 3.  Mechanistic and therapeutic overview of glycosaminoglycans: the unsung heroes of biomolecular signaling.

Authors:  Khushboo Gulati; Krishna Mohan Poluri
Journal:  Glycoconj J       Date:  2015-12-03       Impact factor: 2.916

4.  Review of eprodisate for the treatment of renal disease in AA amyloidosis.

Authors:  Adam Rumjon; Thomas Coats; Muhammad M Javaid
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-02-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.